NCCN VERSION 2 2015

160 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-85
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
responsive, node-positive breast cancer: a phase 3, open-label,
randomised controlled trial. Lancet 2009;374:2055-2063. Available at:
.
253. Tamoxifen for early breast cancer: an overview of the randomised
trials. Early Breast Cancer Trialists' Collaborative Group. Lancet
1998;351:1451-1467. Available at:
254. Arpino G, Green SJ, Allred DC, et al. HER-2 amplification, HER-1
expression, and tamoxifen response in estrogen receptor-positive
metastatic breast cancer: a southwest oncology group study. Clin
Cancer Res 2004;10:5670-5676. Available at:
.
255. Berry DA, Muss HB, Thor AD, et al. HER-2/neu and p53
expression versus tamoxifen resistance in estrogen receptor-positive,
node-positive breast cancer. J Clin Oncol 2000;18:3471-3479. Available
at:
256. De Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysis on
the interaction between HER-2 expression and response to endocrine
treatment in advanced breast cancer. Clin Cancer Res 2005;11:4741-
4748. Available at: .
257. Eppenberger-Castori S, Kueng W, Benz C, et al. Prognostic and
predictive significance of ErbB-2 breast tumor levels measured by
enzyme immunoassay. J Clin Oncol 2001;19:645-656. Available at:
.
258. Knoop AS, Bentzen SM, Nielsen MM, et al. Value of epidermal
growth factor receptor, HER2, p53, and steroid receptors in predicting
the efficacy of tamoxifen in high-risk postmenopausal breast cancer
patients. J Clin Oncol 2001;19:3376-3384. Available at:
.
259. Mass R. The role of HER-2 expression in predicting response to
therapy in breast cancer. Semin Oncol 2000;27:46-52. Available at:
.
260. Paik S, Shak S, Tang G, et al. Expression of the 21 genes in the
Recurrence Score assay and tamoxifen clinical benefit in the NSABP
study B-14 of node negative, estrogen receptor positive breast cancer
[abstract]. J Clin Oncol 2005;23(Suppl 16):Abstract 510. Available at:
.
261. Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive
marker of response to breast cancer therapy. Breast Cancer Res Treat
1998;52:65-77. Available at:
.
262. Dowsett M, Allred C, Knox J, et al. Relationship between
quantitative estrogen and progesterone receptor expression and human
epidermal growth factor receptor 2 (HER-2) status with recurrence in
the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol
2008;26:1059-1065. Available at:
.
263. Early Breast Cancer Trialists' Collaborative G, Davies C, Godwin J,
et al. Relevance of breast cancer hormone receptors and other factors
to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of
randomised trials. Lancet 2011;378:771-784. Available at:
.
264. Early Breast Cancer Trialists' Collaborative G. Effects of
chemotherapy and hormonal therapy for early breast cancer on
recurrence and 15-year survival: an overview of the randomised trials.
Lancet 2005;365:1687-1717. Available at:
.
265. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing
adjuvant tamoxifen to 10 years versus stopping at 5 years after
diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a